Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 6, 2015, Pages 449-459

  Frydecka, Dorota ^a   Misiak, Błażej ^a   Pawlak Adamska, Edyta ^b   Karabon, Lidia ^a,b   Tomkiewicz, Anna ^b   Sedlaczek, Paweł ^a   Kiejna, Andrzej ^a   Beszłej, Jan Aleksander ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

C reactive protein; Cognition; Gene polymorphism; Inflammation; Interleukin 6; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; CHLORPROMAZINE; INTERLEUKIN 6; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OPERATIONAL CRITERIA FOR PSYCHOTIC ILLNESS CHECKLIST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOSIS; REY AUDITORY VERBAL LEARNING TEST; RISK FACTOR; SCALES FOR ASSESSMENT OF POSITIVE AND NEGATIVE SYMPTOMS; SCHIZOPHRENIA; VERBAL FLUENCY TESTS; WECHSLER INTELLIGENCE SCALE; BLOOD; COGNITION DISORDERS; COMPLICATION; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; COGNITION DISORDERS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84939534588     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0533-5     Document Type: Article

References (55)

1. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD (1997) Interleukin-6: structure-function relationships. Protein Sci 6(5):929–955. doi:10.1002/pro.5560060501
2. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8):801–808. doi:10.1016/j.biopsych.2007.09.024
3. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643(1–2):40–49
4. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671. doi:10.1016/j.biopsych.2011.04.013
5. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J (2014) Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 41:23–32. doi:10.1016/j.psyneuen.2013.12.005
6. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32(1):9–15
7. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS (1994) Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51(1):1–10
8. Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275(24):18138–18144. doi:10.1074/jbc.M000379200
9. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig 102(7):1369–1376. doi:10.1172/JCI2629
10. Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A (2012) Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80(2):136–142. doi:10.1111/j.1399-0039.2012.01886.x
11. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, Kowalski J (2010) Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia: a case–control study. Journal of molecular neuroscience: MN 42(1):112–119. doi:10.1007/s12031-010-9365-6
12. Frydecka D, Misiak B, Beszlej JA, Karabon L, Pawlak-Adamska E, Tomkiewicz A, Partyka A, Jonkisz A, Kiejna A (2013) Genetic variants in transforming growth factor-beta gene (TGFB1) affect susceptibility to schizophrenia. Mol Biol Rep. doi:10.1007/s11033-013-2662-8
13. Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K, Fila-Danilow A, Borkowska P, Kowalski J (2013) Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci 25(1):72–82. doi:10.1176/appi.neuropsych.12020021
14. Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP (2013) Lack of association of IL-6 (-174 G > C) and TNF-alpha (-238 G > A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine 61(2):455–458. doi:10.1016/j.cyto.2012.10.028
15. Liu YL, Liu CM, Fann CS, Yang WC, Chen YH, Tseng LJ, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Chen WJ, Hwu HG (2010) Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neurosci Lett 468(3):330–333. doi:10.1016/j.neulet.2009.11.026
16. Gimeno D, Marmot MG, Singh-Manoux A (2008) Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 33(10):1322–1334. doi:10.1016/j.psyneuen.2008.07.006
17. Marsland AL, Petersen KL, Sathanoori R, Muldoon MF, Neumann SA, Ryan C, Flory JD, Manuck SB (2006) Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med 68(6):895–903. doi:10.1097/01.psy.0000238451.22174.92
18. Simpson EE, Hodkinson CF, Maylor EA, McCormack JM, Rae G, Strain S, Alexander HD, Wallace JM (2013) Intracellular cytokine production and cognition in healthy older adults. Psychoneuroendocrinology 38(10):2196–2208. doi:10.1016/j.psyneuen.2013.04.007
19. Mooijaart SP, Sattar N, Trompet S, Lucke J, Stott DJ, Ford I, Jukema JW, Westendorp RG, de Craen AJ (2013) Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study. J Intern Med 274(1):77–85. doi:10.1111/joim.12052
20. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM, Biessels GJ (2014) Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. Psychoneuroendocrinology 40:108–118. doi:10.1016/j.psyneuen.2013.11.011
21. Jordanova V, Stewart R, Davies E, Sherwood R, Prince M (2007) Markers of inflammation and cognitive decline in an African-Caribbean population. Int J Geriatr Psychiatry 22(10):966–973. doi:10.1002/gps.1772
22. Lekander M, von Essen J, Schultzberg M, Andreasson AN, Garlind A, Hansson LO, Nilsson LG (2011) Cytokines and memory across the mature life span of women. Scand J Psychol 52(3):229–235. doi:10.1111/j.1467-9450.2010.00865.x
23. Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E (2011) Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett 32(4):540–544
24. Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11–37. doi:10.1007/978-3-642-25758-2_2
25. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93(1–3):261–265. doi:10.1016/j.schres.2007.03.022
26. Muller N, Myint AM, Schwarz MJ (2012) Immunological treatment options for schizophrenia. Curr Pharm Biotechnol 13(8):1606–1613
27. Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM, Correll CU (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39(6):1230–1241. doi:10.1093/schbul/sbt070
28. Sommer IE, de Witte L, Begemann M, Kahn RS (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 73(4):414–419. doi:10.4088/JCP.10r06823
29. Muller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255(2):149–151. doi:10.1007/s00406-004-0548-4
30. McGuffin P, Farmer A, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48(8):764–770
31. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64(6):663–667
32. Rey A (1964) The clinical examination in psychology. University Press of France, Paris
33. Reitan RM (1955) The relation of the trail making test to organic brain damage. J Consult Psychol 19(5):393–394
34. Benton AL (1968) Differential behavioural effects in frontal lobe disease. Neuropsychologia 6:53–60
35. Kessler J, Denzler P, Markowitsch HJ (1988) Manual Demenz Test - Wrotproduktion (“Supermarktaufgabe). Dementznormen. 10
36. Jensen AR (1965) Scoring the stroop test. Acta Psychol 24(5):398–408
37. Liu YL, Liu CM, Fann CS, Yang WC, Chen YH, Tseng LJ, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Chen WJ, Hwu HG (2010) Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neurosci Lett 468(3):330–333. doi:10.1016/j.neulet.2009.11.026
38. Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N, Velligan D, Walss-Bass C (2013) Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 151(1–3):29–35. doi:10.1016/j.schres.2013.10.019
39. Kim YK, Kim L, Lee MS (2000) Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44(3):165–175
40. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6(4):502–516. doi:10.1007/s11682-012-9186-z
41. Manglam MK, Das A (2013) Verbal learning and memory and psychopathology in schizophrenia. Asian J Psychiatr 6(5):417–420. doi:10.1016/j.ajp.2013.05.009
42. Ekerholm M, Firus Waltersson S, Fagerberg T, Soderman E, Terenius L, Agartz I, Jonsson EG, Nyman H (2012) Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. Psychiatry Res 200(2–3):144–152. doi:10.1016/j.psychres.2012.05.008
43. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ (2010) Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiol Aging 31(10):1700–1709. doi:10.1016/j.neurobiolaging.2008.09.009
44. Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 64(5):532–542. doi:10.1001/archpsyc.64.5.532
45. Dickinson D (2008) Digit symbol coding and general cognitive ability in schizophrenia: worth another look? Br J Psychiatry 193(5):354–356. doi:10.1192/bjp.bp.108.049387
46. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, Fowkes FG (2007) Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc 55(5):700–707. doi:10.1111/j.1532-5415.2007.01158.x
47. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59(3):710–713. doi:10.2337/db09-1163
48. Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7(4):223–230. doi:10.3371/CSRP.MICU.020813
49. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, Yolken R (2013) C-reactive protein is elevated in schizophrenia. Schizophr Res 143(1):198–202. doi:10.1016/j.schres.2012.10.041
50. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B (2012) Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res 198(2):212–215. doi:10.1016/j.psychres.2011.08.014
51. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, Yolken R (2013) C-reactive protein is elevated in schizophrenia. Schizophr Res 143(1):198–202. doi:10.1016/j.schres.2012.10.041
52. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93(1–3):261–265. doi:10.1016/j.schres.2007.03.022
53. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R (2013) Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 150(2):456–459. doi:10.1016/j.jad.2013.04.039
54. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149(1–3):267–271. doi:10.1016/j.psychres.2006.07.011
55. Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, Poznanovic ST, Jovanovic A, Nikolic T, Petronijevic ND (2013) Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatria Danubina 25(1):55–61